中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2014年
6期
482-485
,共4页
龚莉琳%田波%李蓉%汪志红%冯正平%程庆丰%张素华%李启富
龔莉琳%田波%李蓉%汪誌紅%馮正平%程慶豐%張素華%李啟富
공리림%전파%리용%왕지홍%풍정평%정경봉%장소화%리계부
多发性内分泌腺瘤病%原癌基因%基因检测
多髮性內分泌腺瘤病%原癌基因%基因檢測
다발성내분비선류병%원암기인%기인검측
Multiple endocrine neoplasia%Proto-oncogene%Gene test
目的:对一个多发性内分泌腺瘤病2型( multiple endocrine neoplasia 2,MEN2)家系进行RET基因检测,明确诊断和分型,指导治疗、预防及改善预后。方法采用聚合酶链反应和直接基因测序的方法,对一个临床诊断MEN2的家系(共3名家系成员)和3例正常对照的RET原癌基因21个外显子进行测序。结果该家系中的2例患者和1例无症状一级亲属均为RET原癌基因外显子11第634号密码子位点的杂合错义突变TGC→CGC,半胱氨酸→精氨酸( C634R)。结论通过RET基因检测明确该家系为多发性内分泌腺瘤病2A型,对家系中患者的治疗和随访起到了指导作用,并筛查出家系中无症状的基因突变携带者。
目的:對一箇多髮性內分泌腺瘤病2型( multiple endocrine neoplasia 2,MEN2)傢繫進行RET基因檢測,明確診斷和分型,指導治療、預防及改善預後。方法採用聚閤酶鏈反應和直接基因測序的方法,對一箇臨床診斷MEN2的傢繫(共3名傢繫成員)和3例正常對照的RET原癌基因21箇外顯子進行測序。結果該傢繫中的2例患者和1例無癥狀一級親屬均為RET原癌基因外顯子11第634號密碼子位點的雜閤錯義突變TGC→CGC,半胱氨痠→精氨痠( C634R)。結論通過RET基因檢測明確該傢繫為多髮性內分泌腺瘤病2A型,對傢繫中患者的治療和隨訪起到瞭指導作用,併篩查齣傢繫中無癥狀的基因突變攜帶者。
목적:대일개다발성내분비선류병2형( multiple endocrine neoplasia 2,MEN2)가계진행RET기인검측,명학진단화분형,지도치료、예방급개선예후。방법채용취합매련반응화직접기인측서적방법,대일개림상진단MEN2적가계(공3명가계성원)화3례정상대조적RET원암기인21개외현자진행측서。결과해가계중적2례환자화1례무증상일급친속균위RET원암기인외현자11제634호밀마자위점적잡합착의돌변TGC→CGC,반광안산→정안산( C634R)。결론통과RET기인검측명학해가계위다발성내분비선류병2A형,대가계중환자적치료화수방기도료지도작용,병사사출가계중무증상적기인돌변휴대자。
Objective To test the RET-proto-oncogene in a multiple endocrine neoplasia type 2( MEN2) family for confirming the diagnosis and classification , guiding treatment and prevention , and improving the prog-nosis.Methods There were 2 patients of MEN2 with clinical diagnosis and 1 asymptomatic first-degree relative in the pedigree .PCR and direct gene sequencing of PCR produces were used to scan the entire 21 exons of RET-proto-oncogene in the 3 members of the pedigree and 3 normal controls .Results The 2 patients and 1 asympto-matic first-degree relative in the pedigree all had a mutation of the codon 634 in exon 11.It was a heterozygous missense mutation C634R(TGC → CGC).The 3 normal controls showed no abnormalities .Conclusion The gene test of RET proto-oncogene helps to confirm the diagnosis of the pedigree as MEN 2, which can guide the treatment and help identify one asymptomatic mutation carrier .